Transfusion management in thalassemia.
blood
thalassemia
transfusion
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
21
9
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
This review describes the current challenges and recommendations in the transfusion management of thalassemia patients. In addition, it reviews the components of blood safety and blood product modification in special populations. Adverse transfusion reactions are described as are some of the newer technologies being utilized to reduce potential transfusion-associated pathogens. Lastly, research in blood storage and in manufactured blood is briefly described.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-48Informations de copyright
© 2023 New York Academy of Sciences.
Références
Shah, F. T., Sayani, F., Trompeter, S., Drasar, E., & Piga, A. (2019). Challenges of blood transfusions in β-thalassemia. Blood Reviews, 37, 100588.
Lal, A. (2020). Challenges in chronic transfusion for patients with thalassemia. Hematology: the American Society of Hematology Education Program, 2020(1), 160-166.
Cappellini, M. D., Farmakis, D., Porter, J., & Taher, A. (2017). Guidelines for the management of transfusion dependent thalassaemia (TDT) [Internet]. 4th ed. Version 2.0. Thalassaemia International Federation.
American Society of Hematology. (2022). Statement on a strong blood supply. Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/policy-statements/2021/statement-on-a-strong-blood-supply
Franchini, M., Forni, G. L., & Liumbruno, G. M. (2017). Is there a standard-of-care for transfusion therapy in thalassemia? Current Opinion in Hematology, 24(6), 558-564.
Langhi, D., Ubiali, E. M. A., Marques, J. F. C., Verissimo, M. D. A., Leggett, S. R., Silvinato, A., & Bernardo, W. M. (2016). Guidelines on beta-thalassemia major - Regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2016. Revista Brasileira de Hematologia e Hemoterapia, 38(4), 341-345.
Allen, A., Fisher, C., Premawardhena, A., Peto, T., Allen, S., Arambepola, M., Thayalsutha, V., Olivieri, N., & Weatherall, D. (2010). Adaptation to anemia in hemoglobin E-ß thalassemia. Blood, 116(24), 5368-5370.
Olivieri, N. F., Muraca, G. M., O'donnell, A., Premawardhena, A., Fisher, C., & Weatherall, D. J. (2008). Studies in haemoglobin E beta-thalassaemia. British Journal of Haematology, 141(3), 388-397.
Amid, A., Chen, S., Brien, W., Kirby-Allen, M., & Odame, I. (2016). Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis. Blood, 127(9), 1208-1211.
Amid, A., Barrowman, N., Odame, I., & Kirby-Allen, M. (2022). Optimizing transfusion therapy for survivors of haemoglobin Bart's hydrops fetalis syndrome: Defining the targets for haemoglobin-H fraction and “functional” haemoglobin level. British Journal of Haematology, 197(3), 373-376.
Taher, A. T., Radwan, A., & Viprakasit, V. (2015). When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sanguinis, 108(1), 1-10.
Kosaryan, M., Mahdavi, M. R., Roshan, P., & Hojjati, M. T. (2012). Prevalence of alloimmunisation in patients with beta thalassaemia major. Blood Transfusion, 10(3), 396-397.
Cazzola, M., Stefano, P. D., Ponchio, L., Locatelli, F., Beguin, Y., Dessì, C., Barella, S., Cao, A., & Galanello, R. (1995). Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. British Journal of Haematology, 89(3), 473-478.
Cazzola, M., Borgna-Pignatti, C., Locatelli, F., Ponchio, L., Beguin, Y., & Stefano, P. (1997). A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion, 37(2), 135-140.
Kaur, M., Kaur, R., Sood, T., Jindal, G., Kaur, P., & Mittal, K. (2022). Efficacy of packed red blood cell transfusions based on weight versus formula in thalassemic children: An open-label randomized control trial. Transfusion, 62(4), 791-796.
Friedman, D. F., Jawad, A. F., Martin, M. B., Horiuchi, K., Mitchell, C. F., & Cohen, A. R. (2003). Erythrocytapheresis to reduce iron loading in thalassemia. Blood, 102(11), 121.
Berdoukas, V. A., Kwan, Y. L., & Sansotta, M. L. (1986). A study on the value of red cell exchange transfusion in transfusion dependent anaemias. Clinical & Laboratory Haematology, 8, 209-220.
Klein, H. G., Spahn, D. R., & Carson, J. L. (2007). Red blood cell transfusion in clinical practice. Lancet, 370(9585), 415-426.
Schiroli, D., Merolle, L., Quartieri, E., Chicchi, R., Fasano, T., De Luca, T., Molinari, G., Pulcini, S., Pertinhez, T. A., Di Bartolomeo, E., Biguzzi, R., Baricchi, R., & Marraccini, C. (2021). Comparison of two alternative procedures to obtain packed red blood cells for β-thalassemia major transfusion therapy. Biomolecules, 11(11), 1638.
(2022). AABB Standards for Blood Banks and Transfusion Services.
(2021). AABB Standards for a Patient Blood Management Program (3rd ed.).
Cohn, C. S., Delaney, M., Johnson, S. T., & Katz, L. M. (2020). AABB technical manual (20th ed.).
Chou, S. T., Liem, R. I., & Thompson, A. A. (2012). Challenges of alloimmunization in patients with haemoglobinopathies. British Journal of Haematology, 159(4), 394-404.
Milkins, C., Berryman, J., Cantwell, C., Elliott, C., Haggas, R., Jones, J., Rowley, M., Williams, M., & Win, N. (2013). Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfusion Medicine (Oxford, England), 23(1), 3-35.
Patterson, S., Singleton, A., Branscomb, J., Nsonwu, V., & Spratling, R. (2022). Transfusion complications in thalassemia: Patient knowledge and perspectives. Frontiers in Medicine, 9, 772886.
Robinson, S., Harris, A., Atkinson, S., Atterbury, C., Bolton-Maggs, P., Elliott, C., Hawkins, T., Hazra, E., Howell, C., New, H., Shackleton, T., Shreeve, K., & Taylor, C. (2018). The administration of blood components: A British Society for Haematology Guideline. Transfusion Medicine, 28, 3-21.
Graziano, J. H., Piomelli, S., Hilgartner, M., Giardina, P., Karpatkin, M., Andrew, M., Loiacono, N., & Seaman, C. (1981). Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. Journal of Pediatrics, 99(5), 695-699.
Cohen, A. R., Glimm, E., & Porter, J. B. (2008). Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood, 111(2), 583-587.
O'brien, R. T., Pearson, H. A., & Spencer, R. P. (1972). Transfusion-induced decrease in spleen size in thalassemia major: Documentation by radioisotopic scan. Journal of Pediatrics, 81(1), 105-107.
Modell, B. (1977). Total management of thalassaemia major. Archives of Disease in Childhood, 52(6), 489-500.
Galanello, R., & Origa, R. (2010). Beta-thalassemia. Orphanet Journal of Rare Diseases, 5, 11..
Adamkiewicz, T. V., Berkovitch, M., Krishnan, C., Polsinelli, C., Kermack, D., & Olivieri, N. F. (1998). Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: Incidence and predisposing factors. Clinical Infectious Diseases, 27(6), 1362-1366.
Steele, W. R., Dodd, R. Y., Notari, E. P., Haynes, J., Anderson, S. A., Williams, A. E., Reik, R., Kessler, D., Custer, B., & Stramer, S. L. (2021). HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion, 61, 839.
Dodd, R. Y., Crowder, L. A., Haynes, J. M., Notari, E. P., Stramer, S. L., & Steele, W. R. (2020). Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10 Year trends in prevalence, incidence, and residual risk, 2007 to 2016. Transfusion Medicine Reviews, 34(2), 81.
Zou, S., Stramer, S. L., & Dodd, R. Y. (2012). Donor testing and risk: Current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfusion Medicine Reviews, 26, 119.
Stramer, S. L., Notari, E. P., Zou, S., Krysztof, D. E., Brodsky, J. P., Tegtmeier, G. E., & Dodd, R. Y. (2011). HTLV antibody screening of blood donors: Rates of false positive results and evaluation of a potential donor re-entry algorithm. Transfusion, 51, 692.
Bubiński, M., Gronowska, A., Szykuła, P., Woźniak, A., Rodacka, A., Santi, S., Cardoso, M., & Lachert, E. (2022). Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device. Blood Transfusion, 20(5), 395-403.
Aydinok, Y., Piga, A., Origa, R., Mufti, N., Erickson, A., North, A., Waldhaus, K., Ernst, C., Lin, J. S., Huang, N., Benjamin, R. J., & Corash, L. (2019). Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia. British Journal of Haematology, 186(4), 625-636.
Tobian, A. (2022). Pathogen inactivation of blood products. UpToDate, Retrieved from https://www.uptodate.com/contents/pathogen-inactivation-of-blood-products
Yoshida, T., Prudent, M., & D'alessandro, A. (2019). Red blood cell storage lesion causes and potential clinical consequences. Blood Transfusion, 17(1), 27-52.
Pellegrin, S., Severn, C. E., & Toye, A. M. (2021). Towards manufactured red blood cells for the treatment of inherited anemia. Haematologica, 106(9), 2304-2311.